Increasing commitment of the pharma industry to rare diseases

We invite you to take some altitude and gain a broader perspective on the latest trends in R&D across the innovation-driven biopharma industry.

In this TechBio Update, we spotlight key insights from the Citeline Pharma R&D Annual Review 2025, which highlights the growing momentum in the field of rare diseases. The data reveals a remarkable evolution:

• Rare diseases now account for one third of the clinical development pipeline
• The number of rare diseases targeted by the pharmaceutical industry has doubled over the past decade
• Alimentary and metabolic disorders represent the largest share, comprising nearly a quarter of all targeted conditions

What a transformation and a clear signal of the sector’s increasing commitment to unmet medical needs.

Stay tuned to discover soon the contribution of Quantum BioVenture Studio to advancing R&D in rare diseases and how AI is instrumental to this endeavor.

Discover the full Citeline report here : Pharma R&D 2025 | Citeline